Catalent - CTLT Stock Forecast, Price & News

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Catalent Trading Up 0.8 %

CTLT opened at $110.85 on Tuesday. The firm has a market cap of $19.87 billion, a price-to-earnings ratio of 40.16, a PEG ratio of 1.68 and a beta of 1.29. The company has a current ratio of 2.89, a quick ratio of 2.25 and a debt-to-equity ratio of 0.90. Catalent has a 12 month low of $86.34 and a 12 month high of $142.64. The stock has a fifty day moving average price of $107.64 and a 200-day moving average price of $103.45.

Insider Transactions at Catalent

In other news, CEO Alessandro Maselli sold 816 shares of the business's stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total value of $87,230.40. Following the completion of the transaction, the chief executive officer now directly owns 25,083 shares of the company's stock, valued at approximately $2,681,372.70. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Alessandro Maselli sold 816 shares of the business's stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total transaction of $87,230.40. Following the transaction, the chief executive officer now directly owns 25,083 shares in the company, valued at approximately $2,681,372.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Kay A. Schmidt sold 323 shares of the business's stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total value of $34,528.70. Following the transaction, the senior vice president now owns 13,455 shares in the company, valued at $1,438,339.50. The disclosure for this sale can be found here. In the last three months, insiders sold 4,462 shares of company stock valued at $476,951. Corporate insiders own 0.53% of the company's stock.